Ozempic (semaglutide) is best known for lowering blood sugar in type 2 diabetes, but its benefits extend well beyond glucose control. Clinical trials and real-world data show meaningful improvements in cardiovascular risk, kidney function, blood pressure, and liver health. Some of these effects stem directly from the drug’s mechanism, while others follow from the significant weight loss it promotes.
Blood Sugar Control
Ozempic’s primary job is bringing down blood sugar levels in people with type 2 diabetes, and it does this effectively. In real-world studies of patients on the 1.0 mg weekly dose, average A1c dropped by 1.2 percentage points. Patients who stayed on the medication consistently saw an even larger reduction of 1.4 percentage points. To put that in perspective, an A1c drop of 1 point or more is considered clinically significant and can meaningfully lower the risk of diabetes complications like nerve damage, vision loss, and kidney disease.
The drug works by mimicking a gut hormone called GLP-1 that your body naturally produces after eating. This hormone signals your pancreas to release insulin when blood sugar rises, slows down how quickly food leaves your stomach, and reduces the amount of sugar your liver dumps into your bloodstream. The result is smoother, more stable blood sugar levels throughout the day rather than sharp spikes after meals.
Cardiovascular Risk Reduction
Heart disease is the leading cause of death in people with type 2 diabetes and obesity, which makes the cardiovascular data around semaglutide particularly important. The SELECT trial, a large randomized study reported by the American College of Cardiology, found that semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo in adults with overweight or obesity. This benefit held even in participants who did not have diabetes.
Part of this protection likely comes from the drug’s effects on blood pressure. A meta-analysis reviewed by the American College of Cardiology found that semaglutide consistently lowers systolic blood pressure by about 5 mmHg, regardless of where a person’s blood pressure starts. That may sound modest, but population-level data consistently show that a sustained 5 mmHg drop in systolic pressure translates to a meaningful reduction in heart attack and stroke risk over time.
Weight Loss
Although Ozempic is approved for diabetes rather than weight management specifically, substantial weight loss is one of its most visible effects. Over 68 weeks of treatment, patients in clinical trials lost roughly 15% of their body weight on average. This happens through several overlapping pathways: the drug slows stomach emptying so you feel full longer, it reduces appetite signals in the brain, and it appears to lower the reward value your brain assigns to food.
For many people, this degree of weight loss improves or resolves conditions tied to excess weight, including sleep apnea, joint pain, and insulin resistance. It also contributes to the blood pressure and cardiovascular benefits described above, creating a cascade of metabolic improvements that go beyond what the number on the scale suggests.
Kidney Protection
The FLOW trial tested semaglutide specifically in people with type 2 diabetes and chronic kidney disease. The results were striking: semaglutide reduced major kidney disease events by 24% compared to placebo. In concrete terms, 18.7% of patients on semaglutide experienced a serious kidney outcome (kidney failure, a major decline in kidney filtration, or death from kidney or cardiovascular causes) versus 23.2% on placebo over about 3.4 years.
The drug also slowed the rate at which kidney function declined. Patients on semaglutide were 27% less likely to experience a sustained 50% or greater drop in their kidney filtration rate. For people already managing kidney disease alongside diabetes, this represents a meaningful delay in the progression toward dialysis or transplant. Notably, the trial enrolled patients who were already on standard kidney-protective medications, so semaglutide provided benefits on top of existing treatment.
Liver Fat Reduction
Fatty liver disease is extremely common in people with type 2 diabetes and obesity, and it can progress to inflammation and scarring if left unchecked. A systematic review and meta-analysis found that semaglutide reduced liver fat content by about 5 percentage points compared to placebo. While that number sounds small in isolation, liver fat levels in affected individuals typically range from 10% to 30%, so a 5-point reduction can represent a substantial proportion of the excess fat being cleared. Reducing liver fat can lower inflammation and slow or halt the progression toward more serious liver damage.
Reduced Alcohol and Nicotine Cravings
One of the more unexpected findings around semaglutide involves its apparent effects on addictive behaviors. A study published in JAMA Psychiatry found that weekly semaglutide injections reduced alcohol cravings, lowered the number of drinks consumed on drinking days, and cut the frequency of heavy drinking days in adults with alcohol use disorder. By the second month of treatment, nearly 40% of people on semaglutide reported zero heavy drinking days, compared to 20% on placebo.
A smaller subset of participants who smoked cigarettes also showed significantly greater reductions in daily cigarette use compared to placebo. Researchers believe semaglutide may dampen the brain’s reward response to substances like alcohol and nicotine through the same pathways it uses to reduce food cravings. These findings are still early, and semaglutide is not approved for addiction treatment, but the pattern is consistent enough to drive larger studies.
Effects on PCOS Symptoms
Polycystic ovary syndrome (PCOS) is closely tied to insulin resistance, and semaglutide appears to improve several features of the condition. By promoting weight loss and improving how the body responds to insulin, the drug can help regulate hormone levels that drive PCOS symptoms. Some research suggests that GLP-1 receptor agonists like semaglutide may improve menstrual regularity, likely through these combined effects on weight, insulin sensitivity, and the hormonal imbalances that follow. Ozempic is not approved for PCOS, but clinicians increasingly prescribe it off-label for patients who have both insulin resistance and PCOS-related symptoms.
How Ozempic Is Taken
Ozempic is a once-weekly injection, typically self-administered in the abdomen, thigh, or upper arm using a prefilled pen. The dose starts low and increases gradually to reduce side effects, particularly nausea. You begin at 0.25 mg weekly for the first four weeks, then move to 0.5 mg. From there, your prescriber may increase the dose to 1 mg or up to a maximum of 2 mg depending on your blood sugar response and how well you tolerate the medication.
This slow ramp-up matters because gastrointestinal side effects, especially nausea, decreased appetite, and occasional vomiting, are the most common complaints. They tend to be worst during dose increases and often improve within a few weeks as your body adjusts. Taking the injection on the same day each week helps maintain steady drug levels, though the specific day of the week doesn’t matter.